A comparative review of colony stimulating factors

Drugs

Volumn 54, Issue 5, 1997, Pages 709-729

  Nemunaitis, John ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CELL PROLIFERATION; CELL TRANSPLANTATION; DRUG TOXICITY; GRAFT FAILURE; HUMAN; LEUKEMIA; MACROPHAGE; MYCOSIS; NEUTROPENIA; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0030722131     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754050-00004     Document Type: Review

References (231)

1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutrupenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70
2. Gabrilove JL, Jakibowski A, Scher H, et al. Effect of granulocytc colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988; 318 (22): 1414-22
3. Neidhart J, Mangalik A, Kohler W, et al. Granulocyte colonystimulating factor stimulates recovery of granulocytes in patients receiving dose intensive chemotherapy without bone marrow transplantation. J Clin Oncol 1989; 7(1): 1685-92
4. Kotaket T, Miki T, Akaza H, et al. Effect of recombinant granulocyle colony stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol 1991; 27 (4): 253-7
5. Chung YS, Sowa M, Kato Y, et al. A clinical study on the effect of recombinant human G-CSF in gastric cancer patients with neutropenia induced by chemotherapy (EAP). J Jpn Soc Cancer Ther 1991; 26: 802-7
6. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-24
7. Pettengell R, Gurney G, Randford J, et al. Granulocyte colony stimulating factor to prevent dose limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80 (6): 1430-6
8. Penella J, Hodgetts J, Lomax L, et al. Can cytotoxic dose-intensive be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13 (3): 652-9
9. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13 (7): 1564-71
10. Nguyen B, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995; 13 (10): 2629-36
11. Fukuoka M, Masuda N, Takada M, et al. Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Semin Oncol 1994; 21 (1 Suppl.): 43-7
12. Ochiai K, Terashima Y. Chemotherapy and granulocyte colony-stimulating factor in ovarian cancer. Semin Oncol 1994; 21 (1 Suppl. ): 23-8
13. Fischer JR, Manegold C, Bulzehruck H, et al. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced Stage IIIA/B non-small cell lung cancer. Semin Oncol 1994; 21 (3 Suppl.): 20-7
14. Mori K, Saitoh Y, Tominage K. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer. Eur J Cancer 1993; 29A (5): 677-80
15. 5. Avilés A, Diaz-Maqueo JC, Talavera A, et al. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leuk Lymphoma 1994; 15: 153-7
16. Vokes EE, Haraf DJ, Mick R, et al. Intensified concomitant chemo/radiotherapy with and without filgrastim for poor- prognosis head and neck cancer. J Clin Oncol 1994; 12(11): 2351-9
17. Bertini M, Freiline R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994; 5: 895-900
18. Gebbia V, Valenza R, Testa A, et al. Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer 1994; 30A: 1734-6
19. Christman K, Saltz L, Schwartz G, et al. Granulocytc colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression? J Nat Cancer Inst 1993; 85 (10): 826-7
20. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56 (6): 809-13
21. Eguchi K, Sasaki S, Tamura T, et al. Dose escalation study of recombinant human granulocyte-colony stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res 1989; 49 (18): 5221-4
22. Eguchi K, Shinkai T, Sasaki Y, et al. Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res 1990; 81 (11): 1168-74
23. Ota K, Ariyoshi Y, Fukuoka M, et al. Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer: rG-CSF Cooperation Study Group. Gan To Kagaku Ryoho 1990; 17 (1): 65-71
24. Tsukimoto I, Hanawa Y, Takaku F, et al. Clinical evaluation of recombinant human G-CSF in children with cancer. Rinsho Ketsueki 1990; 31 (10): 1647-55
25. Kosaka T, Suzaki Y, Kinoshita K, et al. Effect of rhG-CSF on the neutropenia induced by chemotherapy for relapsed gastric carcinoma. J Jpn Soc Cancer Ther 1991; 26: 51-5
26. Kudoh S, Fukuoka M, Negoro S, et al. Weekly dose intensive chemotherapy in patients with small cell lung cancer: a pilot study. Am J Clin Oncol 1992; 15: 29-34
27. Oyama A, Ota K, Asano S, et al. Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma. Nippon Gan Chiryo Gakkai Shi 1990; 25 (8): 1619-34
28. Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 1990; 66 (9): 1904-9
29. Oyama A, Ota K, Asano S, et al. A double blind crossover clinical induced by chemotherapy for non-Hodgkin's lymphoma. Nippon Gan Chiryo Gakkai Shi 1990; 25 (10): 2533-48
30. Ogawa M, Masaoka T, Mizoguchi H, et al. A phase III study of KRN8601 (rhG-CSF) on neutropenia induced by chemotherapy for malignant lymphoma - a multi-institutional placebo controlled double blind comparative study. Gan To Kagaku Ryoho 1990; 17 (3): 365-73 31.
31. Niitsu N, Umeda M, Biweekly COP-BLAM (cyclophosphamide. vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. Eur J Haematol 1996; 56: 163-7
32. Bronchud MH, Howell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121-5
33. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-70
34. Noda K, Eguchi K, Nakasa K, et al. Dose escalation study of VM-26 with CDDP and rhG-CSF in patients with small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 1991; 10: 263
35. Demetri GD, Younger J, Shapiro C, et al. A phase I study of dose-intensified CAF chemotherapy with adjunctive r-metHuG-CSF (G-CSF) in patients with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1992; 11: 108
36. Parker BA, Anderson JR, Canellos GP, et al. Dose escalation study of CHOP plus etoposide (CHOPE) without and with rhG-CSF in untreated non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol 1991; 10: 283
37. Callari A, Gebbia V, Testa A, et al. A phase Ml study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. Acta Oncol 1994; 33 (8): 925-9
38. O'Brien MER, Nicolson M, Montes A, et al. Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer. Br J Cancer 1994; 70: 980-3
39. Bitran JD, Samuels BL, Mirsik S, et al. A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res 1995; 1: 185-8
40. Fountzilas G, Skarlos D, Giannakakis T, et al. Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer. Eur J Cancer 1994; 30A: 965-9
41. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13 (5): 1152-9
42. Link CJ, Bicher A, Kohn EC, et al. Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy. Blood 1994; 83 (5): 1188-92
43. Lilenbaum RC, Ratain M, Miller AA, et al. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol 1995; 13 (9): 2230-7
44. Calvert AH, Lind MJ, Shazal-Aswad S, et al. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. Semin Oncol 1994; 21 (5): 1-6
45. Jett JR, Kirschling RJ, Jung SH, et al. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol 1995; 22 (3): 75-7
46. Crowford J, O'Rourke MA. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. Semin Oncol 1994; 21 (5): 73-8
47. Schiller JH, Storer B, Tutsch K, et al. A phase 1 trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 1994; 21 (5): 9-14
48. Eguchi K, Etou H, Miyachi S, et al. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur J Cancer 1994; 30A (2): 188-94
49. O'Reilly SM, Smith DB, Newlands ES, et al. Dose intensification in the treatment of patients with testicular germ cell tumors [abstract]. Eur J Cancer 1994; 30A (5): 723
50. DelMastro L, Garrone O, Sertoli MR, et al. A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. Eur J Cancer 1994; 30A (5): 606-10
51. Gebbia V, Testa VA, Cannata G, et al. A prospective randomized trial of thymopentin versus granulocyte colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res 1994; 14: 731-4
52. Gridelli C, De Placido S, Pepe R, et al. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur J Cancer 1993; 29A (12): 1729-31
53. Lind MJ, Gumbrell L, Cantwell BMJ, et al. The use of granulocyte colony stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer 1995; 71 (3): 610-3
54. Bissett D, Jofrell D, Harnett AN, et al. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (lenograstim) support. Br J Cancer 1995; 71: 1279-82
55. Colucci G, Romito S, Gebbia V, et al. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM). Br J Cancer 1995; 72: 1245-50
56. Frasci G, Comella G, Comella P, et al. Mitoxantrone plus vinorelbine with granulocyte colony stimulating factor (G-CSF) support in advanced breast cancer patients: a dose and schedule finding study. Breast Cancer Res Treat 1995; 35: 147-56
57. Miles DW, Foggarty CM, Ash RM, et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12 (1): 77-82
58. Masuda N, Fukouka M, Kidoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 1994; 12 (1): 90-6
59. Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994; 12 (3): 483-8
60. Miller AA, Hargis JB, Lilenbaum RC, et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 1994; 12 (12): 2743-50
61. Savarese DMF, Denicoff AM, Berg SL, et al. Phase I study of high-dose prioxantrone with granulocyte colony-stimulating factor. J Clin Oncol 1993; 11 (9): 1795-803
62. Karato A, Sasaki Y, Shinkai T, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11 (10): 2030-5
63. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granu- locyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11 (10): 2010-20
64. Tanosaki R, Okamoto S, Akatsuka N, et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 1994; 74 (7): 1939-44
65. Frasci G, Perillo G, Comella G, et al. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced non-small cell lung cancer. Cancer 1995; 75 (7): 1578-85
66. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 1994; 121: 492-501
67. Mayordomo JI, Reivera F, Diaz-Puente T, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87 (11): 803-8
68. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891-5
69. Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7: 1791-9
70. Peters WP. The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation. Semin Hematol 1989; 26 (2): 18-23
71. Auer I, Ribas A, Gale RP. What is the role of recombinant colony-stimulating factors in bone marrow transplantation. Bone Mar Transpl 1990; 6: 79-87
72. Masaoka T, Takaku F, Kato S, et al. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol 1989; 17: 1047-50
73. Kennedy MJ, Davis J, Passos-Coelho J, et al. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroneroxycyclophosphamide-purged marrow in women with metastatic breast cancer. Cancer Res 1993; 53: 5424-8
74. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim on bone marrow transplantation. Lancet 1994; 343: 696-8
75. Schniban JR, Chao NJ, Long CD, et al. Granulocyle colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84 (5): 1680-4
76. Vey N, Molnar S, Faucher C, et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994; 14: 779-82
77. Clark RE, Shlebak AA, Greagh MD. Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leuk Lymphoma 1994; 16: 141-6
78. Khwaja A, Mills W, Leveridge K, et al. Efficacy of delayed granulocyte colony stimulating factor after autologous BMT. Bone Marrow Transplant 1993; 11: 479-82
79. Madero L, Muñoz A, Diaz de Heredia A, et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Bone Marrow Transplant 1995; 15: 349-51
80. Gomez AT, Jimenez MA, Alvarez MA, et al. Optimal timing of granulocyte colony-stimulating (actor (G-CSF) administration after bone marrow transplantation: a prospective randomized study. Ann Hematol 1995; 71: 65-70
81. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7
82. Azevedo WM, Aranha FJP, Gouvea JV, et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16: 647-53
83. Locatelli F, Zecca M, Ponchio L, et al. Pilot trial of combined administration of erythropoietin and granulocyte colony stimulating factor to children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 929-35
84. Takahashi S, Okamoto SI, Shirafuji N, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant 1994; 13: 239-45
85. Lickliter JD, Roberts AW, Grigg AP. Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. Aust NZ J Med 1994; 24: 541-6
86. Van Heof MEHM, Baumann I, Lange C, et al. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 217-24
87. Crown J, Kritz A, Vahdat L, et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11 (6): 1144-9
88. Yeung AW, Pang YK, Tsnag YC, et al. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. Cancer 1994; 73 (7): 1960-70
89. Demirer T, Rowley S, Buckner CD, et al. Peripheral blood stem cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13 (7): 1714-9
90. Leyvraz S, Ketterer N, Perey L, et al. Intensification of chemotherapy for the treatment of solid tumors: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor. Br J Cancer 1995; 72: 178-82
91. Sica S, Di Mario A, Salutari P, et al. Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. Amer J Hematol 1994; 46: 18-23
92. Albertzzi L, Rosti G, Ferrari E, et al. Mobilization with high-dose epirubicin and G-CSF in patients with breast cancer undergoing PBSC supported ICE program [abstract]. Bone Marrow Transplant 1994; 14 (1): S31
93. To LB, Basser RL, Lver I, et al. Multiple cycles of sub-maximal high-dose therapy and peripheral blood rescue for poor prognosis breast carcinoma [abstract]. Bone Marrow Transplant 1994; 14(1): S29
94. Shea T, Graham M, Bernard S, et al. A clinical and pharmacokinetic study of high-dose carboplatin. paclitaxel, granulocyte colony-stimulating factor and peripheral blood stem cells in patients with unresectable or metastatic cancer. Semin Oncol 1995; 22 (5): 80-5
95. Kotasek D, Sage RE, Dale BM, et al. Dose intensive therapy with autologous blood stem cell transplantation in breast cancer. Aust NZ J Med 1994; 24: 288-95
96. Vahdat L, Raptis G, Fennelly, et al. Rapidly cycled course of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1995; 1: 1267-73
97. Long GD, Negrin RS, Hoyle CF, et al. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 1995; 76 (5): 860-8
98. Venturini M, Del Mastro L, Metioli G, et al. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. Cancer 1994; 74 (8): 2300-6
99. Tarella C, Caracciolo D, Gavarotti P, et al. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Bone Marrow Transplant 1995; 16: 223-8
100. Menichella G, Peorelli L, Scambia G, et al. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotrans-plantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplant 1994; 14: 907-12
101. Croockewit S, Raymakers R, Trilsbeek C, et al. Primitive multilineage progenitor cells predominate in peripheral blood early after mobilization with high-dose cyclophosphamide and GM-CSF or G-CSF. Leukemia 1994; 8 (12): 2194-9
102. Brugger W, Birken R, Bertz H, et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP-16, ifosfamide and cisplatin. Br J Haematol 1993; 84: 402-7
103. Fields KK, Elfenbein GJ, Perkins JB, et al. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion. Semin Oncol 1994; 21 (5): 86-92
104. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13 (6): 1328-35
105. Nemunaitis J. Cytokine-mobilized peripheral blood progenitor cells. Semin Oncol 1996; 23 (4): 9-14
106. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-3
107. Geissler K, Valent P, Mayer P, et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates - synergism with recombinant human granulocyte-macrophage colony stimulating factor. Blood 1990; 75: 2305-10
108. Fibbe WE, Vellenga E, Bezwoda WR, et al. Thrombopoietic effect of interleukin-3 (IL-3) after autologous bone marrow transplantation (ABMT) in patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD): results from a phase III placebo-controlled study [abstract]. Blood 1994; 84 Suppl. 1: 92a
109. van der Wall E, Nooijen WJ, Baars JW, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer a practical approach. Br J Cancer 1995; 71: 857-62
110. Schiller G, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86 (1): 390-7
111. Sheridan WP, Begley CG, To LP, et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hematopoiesis after high dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-11
112. Bolwell BJ, Fishleder A, Andersen SW, et al. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant 1993; 12: 609-14
113. Haynes A, Hunter A, McQuaker G, et al. Engraftment characteristics of peripheral blood stem cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-63
114. Hohaus S, Goldschmidt H, Ehrhardt R, et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exper Hematol 1993; 21: 508-14
115. Kanold J, Rapatel C, Berger M, et al. Use of G-CSF alone to mobilize peripheral blood stem cells for collection from children. Br J Haematol 1994; 88: 633-5
116. Schmitz N, Dreger P, Zander AR, et al. Results of a randomized, controlled, multi center study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261-6
117. Haas R, Moos M, Karcher A, et al. Sequential high-dose therapy with peripheral blood progenitor cell support in low grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12 (8): 1685-92
118. Nademanee A, Sniecinski I, Schmidt GM, et al. High dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor mobilized peripheral blood stem cells. J Clin Oncol 1994; 12 (10): 2176-86
119. Cartelazzo S, Viero P, Bellavita P, et al. Granulocyte colony stimulating factor following peripheral blood progenitor cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13 (4): 935-41
120. Pigaditou A, Marini G, Johnson PWM, et al. Myelo-ablative therapy with peripheral blood progenitor cell (PBPC) support in patients with haematological malignancy. Ann Oncol 1995; 6: 53-8
121. Rosenfeld C, Collins R, Piñeiro L, et al. Allogeneic blood cell transplantation without post-transplant colony stimulating factors in patients with hematopoietic neoplasm: a phase II study. J Clin Oncol 1996; 14(4): 1314-9
122. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony stimulating factor). Blood 1995; 85 (15): 1666-72
123. Nemunaitis J, Rosenfeld CS, Collins R, et al. Allogenic transplant combining mobilized blood and bone marrow in patients with refractory hematologic malignancies. Transfusion 1995; 35: 666-73
124. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-65
125. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogenic peripheral blood stem cells mobilized by recombinant human granulocytc colony stimulating factor. Blood 1995; 85: 1655-8
126. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81 (10): 2496-502
127. Dale CD. Hematopoietic growth factors for the treatment of severe chronic neutropenia. Stem Cells 1995; 13: 94-100
128. Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994; 88: 723-30
129. Dale DC, Bolyard AA, Hammond WP. Cyclic neutropenia: natural history and effects of long-term treatment with recombinant human granulocyte colony-stimulating factor. Cancer Invest 1993; 11 (2): 219-23
130. Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA 1993; 270 (9): 1132-3
131. Visani G, Manfroi S. G-CSF in the biology and treatment of acute myeloid leukemias. Leuk Lymphoma 1995; 18: 423-8
132. Ohno R, Naoe T, Kanamura A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83 (15): 2086-92
133. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323 (13): 871-7
134. Kantarjian HM, Estey E, O' Brien S, et al. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 1993; 72 (10): 2950-5
135. Larson RA, Linker CA, Didge RK, et al. Granulocyte colony-stimulating factor (filgrastim: G-CSF) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemia receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B Study 9111 [abstract]. Proc Am Soc Clin Oncol 1994; 13: 305
136. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332 (25): 1678-83
137. Scherrer R, Geissler K, Kyrle PA, et al. Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol 1993; 66: 283-9
138. Ohno R, Hiraoka A, Tanimoto M, et al. No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Blood 1993; 81 (2): 561-2
139. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12 (4): 671-8
140. Ottmann O, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemo/radiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86 (2): 444-50
141. Liang DC, Chen SH, Lean SF. Role of granulocyte colony stimulating factor as adjunct therapy for septicemia in children with acute leukemia. Am J Hematol 1995; 48: 76-81
142. Imamura M, Kobayashi M, Kobayashi S, et al. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 1994; 68: 163-6
143. Ganser A, Seipelt G, Verbeek W, et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994; 81 (3): 369-75
144. Bessho M, Jinnai I, Hirashima K, et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells 1994; 12: 604-15
145. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin and granulocyte colony stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party. Blood 1998; 85 (5): 1348-53
146. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes [abstract no. 768]. Blood 1993; 82 (10): 196a
147. Negrin RS, Stein R, Doberty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87 (10): 4076-81
148. Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte macrophage colony stimulating factor. J Clin Oncol 1989; 7: 159-67
149. Jost LM, Pichert G, Stahel RA. Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol 1992; 1: 439-42
150. Petros WP, Peters WP. Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 1993; 20 (1): 94-9
151. de Bries EGE, Biesma B, Willemse PHB, et al. A double-blind placebo-controlled study with granulocyte-macrophage colony stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991; 51: 116-22
152. Gerhartz HH, Engelhard M, Meusers P, et al. Randomized double blind placebo controlled phase III study of recombinant human granulocyte macrophage colony stimulating factor as adjunct to induction treatment of high grade malignant non-Hodgkin's lymphomas. Blood 1993; 82 (8): 2329-39
153. Yau JC, Neidhart JA, Triozzi P, et al. Randomized placebo-controlled trial of granulocyte macrophage colony stimulating factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol 1996; 51: 289-95
154. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-8
155. Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in autologous marrow transplantation for lymphoid malignancies. In: Dicke KA, editor. Autologous bone marrow transplantation: proceedings of the third international symposium. Houston: University of Texas, 1989: 631-6
156. Devereaux S, Linch DC, Gribben JG, et al. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant 1989; 4: 49-54
157. Blazar BR, Kersey JH, McGlave PB, et al. In vivo administration of recombinant human granulocyte macrophage colony stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989; 73: 849-57
158. Link H, Freund M, Kirchner H, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) after bone marrow transplantation. Behring Inst Mitt 1988; 83: 313-9
159. Lazarus HM, Coiffer B, Hyatt M, et al. Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group trial. Blood 1991; 78: 830-7
160. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte macrophage colony stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869-76
161. Rabinowe SN, Nemunaitis J, Armitage J, et al. The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol 1991; 28 Suppl. 2: 6-16
162. Gorin NC, Coiffier B, Hayat M, et al. rhuGM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double blind study [letter]. Bone Marrow Transplant 1991; 7 Suppl. 2: 82
163. Advani R, Chao NJ, Horning SJ, et al. Granulocyte macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116: 183-9
164. Gulati SC, Bennett CL. Granulocyte macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Intern Med 1992; 116: 177-82
165. Schriber JR, Negrin RS, Chao NJ, et al. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia 1993; 7 (10): 1491-5
166. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplant in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204
167. Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant granulocyte macrophage colony stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245-53
168. Bolger GB, Sullivan KM, Storb R, et al. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1986; 1: 21-30
169. Bierman P, Appelbaum F, Oette D, et al. Granulocyte macrophage colony stimulating factor for engraftment failure following autologous or allogenic bone marrow transplantation [abstract]. Blood 1992; 80 (1): 269a
170. Nemunaitis J. The role of GM-CSF and G-CSF in stem cell transplantation. Oncology 1993; 7 (12): 27-32
171. Klingermann HG, Eaves AC, Barnett MJ, et al. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin Invest Med 1990; 13: 77-81
172. Vose JM, Bierman PJ, Dessinger A, et al. The use of recombinant human granulocyte macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 1991; 7: 139-43
173. Dewitte T, Gratwohl A, Vanderley N, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) reduces infection-related mortality after allogeneic T-cell depleted bone marrow transplantation. Bone Marrow Transplant 1991; 7 Suppl. 2: 83
174. Powels R, Smith C, Mulan S, et al. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: a double-blind placebo controlled trial. Lancet 1990; 336: 1417-20
175. Anasetti C, Anderson G, Appelbaum FR, et al. Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors [abstract]. Blood 1993; 82: 454a
176. Nemunaitis J, Rosenfeld C, Ash R, et al. Phase III randomized double blind placebo controlled trial of rhGM-CSF following allogeneic bone marrow transplant. Bone Marrow Transplant 1995; 15: 949-54
177. Hiraoka A, Massaoka T, Moriyama, et al. A double-blind, placebo-controlled test of recombinant human nonglycosylated GM-CSF for allogeneic bone marrow transplantation. Bone Marrow Transplant. In press
178. Nemunaitis J, Buckner CD, Appelbaum FR, et al. Phase I/II trial of recombinant human granulocyte macrophage colony stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77: 2065-71
179. Nemunaitis J, Anasetti C, Buckner CD, et al. Long-term follow-up of 103 patients who received rhGM-CSF after unrelated donor bone marrow transplant (BMT) (letter). Blood 1993; 81 (3): 865
180. Nemunaitis J, Anasetti C, Storb R, et al. Phase II trial of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992; 79 (10): 2572-7
181. Naparstek E, Hardogen Y, Ben-Shahar A, et al. Enhanced marrow recovery by short preincubation B of marrow allografts with human recombinant Interleukin-3 and granulocyte macrophage colony stimulating factor. Blood 1992; 80: 1673-8
182. Nemunaitis J, Anasetti C, Bianco J, et al. rhGM-CSF after allogeneic bone marrow transplant from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis. Leuk Lymphoma 1993; 10: 177-81
183. Chap L, Schiller G, Nimer SD. The use of recombinant GM-CSF following allogeneic bone marrow transplantation for aplastic anemia. Bone Marrow Transplant. In press
184. Nemunaitis J, Rosenfeld C, Collins R, et al. Allogeneic transplantation combining mobilized blood and bone marrow in patients with refractory hematologic malignancies. Transfusion 1995; 35: 666-73
185. Lowry PA, Tabbara IA. Peripheral hematopoietic stem cell transplantation: current concepts. Exp Hematol 1992; 20: 937-42
186. Kotasek D, Shephers KM, Sage RE, et al. Factors affecting blood stem cell collections following high dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-7
187. Jagannath S, Vesole DH, Glenn L, et al. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80 (7): 1666-72
188. Boiron JM, Marit G, Faberes C, et al. Collection of peripheral blood stem cells in multiple myeloma following single high dose cyclophosphamide with and without recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49-55
189. To LB, Roberts MM, Haylock DM, et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9 (4): 277-84
190. Rosenfeld CS, Gremba C, Shadduck RK, et al. Engraftment with peripheral blood stem cells using non-controlled rate cryopreservation: comparison with autologous marrow transplantation. Exp Hematol 1994; 22: 290-4
191. Ross AA, Copper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82 (9): 2605-10
192. Kessinger A, Armitage JO, Smith DM. High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-5
193. Moss TJ, Sanders DG, Lasky LC, et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cell. Blood 1990; 76: 1879-83
194. Vose JM, Bierman PJ, Anderson JR, et al. High dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin's lymphoma: evaluation of event-free survival bases on histologic subtype and rescue product. Proc Am Soc Clin Oncol 1992; 11: 318-23
195. Sureda A, Brunei S, Martinez E, et al. A randomized study comparing cyclophosphamide vs cyclophosphamide + granulocyte macrophage colony stimulating factor as mobilization therapy for multiple myeloma patients. Bone Marrow Transplant 1995; 15 Suppl. 3: 74-7
196. Tepler I, Cannistra SA, Frei E. Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatients high dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993; 11 (8): 1583-91
197. Haas R, Hohaus S, Egerer G, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 1992; 9: 459-65
198. Ho AD, Cluck S, Germond C, et al. Optimal liming for collections of blood progenitor cells following induction chemotherapy and granulocyte macrophage colony stimulating factor for autologous transplantation in advanced breast cancer. Bone Marrow Transplant 1992; 6: 269-75
199. Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high dose carboplatin administered with recombinant human granulocyte macrophage colony stimulating factor and repeated infusions of autologous peripheral blood progenitor cells: a novel and effective method for delivering multiple courses of dose intensive therapy. J Clin Oncol 1992; 10: 464-73
200. Kritz A, Crown JP, Motzer RJ, et al. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high dose chemotherapy plus granulocyte macrophage colony stimulating factor: a randomized trial. Cancer 1993; 71 (8): 2515-21
201. Ho AD, Haas R, Korbbling M, et al. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation. Bone Marrow Transplant 1991; 7: 13-7
202. Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy. Blood 1993; 81(7): 1709-19
203. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81 (7): 1883-8
204. Nemunaitis J, Rosenfeld CER, Bolwell B, et al. Phase II randomized trial comparing SDZ ILE 964 (rhIL-3) to sequential and combination administration of rhIL-3 and leukine or neupogen in the mobilization of peripheral blood progenitor cells for autologous transplant (PBSCT) in patients with lymphoid malignancy or breast cancer [abstract]. Blood 1993; 82 (10): 365a
205. Schuster MW. Will cytokines alter the treatment of myelodysplastic syndrome? Am J Med Science 1993; 305 (2): 72-8
206. Harmenberg J, Hoglund M, Hellstrom-Lindberg E. G- and GM-CSF in oncology and oncological haematology. Eur J Haematol 1994; 52: 1-28
207. Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317 (25): 1545-52
208. Stein RS. Clinical use of growth factors in the myelodysplastic syndromes. Am J Med Sci 1994; 307 (5): 360-7
209. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86 (2): 457-62
210. Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind randomized placebo controlled trial in therapy of adult patients wit de novo acute myeloid leukemia (AML). Leukemia 1995; 9: 3-9
211. Hansen PB, Johnsen HE, Jensen L, et al. Priming and treatment with molgramostim (rhGM-CSF) in adult high risk acute myeloid leukemia during induction chemotherapy: a prospective randomized pilot study. Eur J Haematol 1995; 54: 296-303
212. Stone RM, Berg DT, George SL, et al. Granulocyte macrophage colony stimulating factor after initial chemotherapy for patients at least 60 years old with primary acute myeloid leukemia. N Engl J Med 1995; 332: 1671-7
213. Hiddemann W, Wormann B, Reuter C, et al. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors. Semin Oncol 1994; 21 (6): 33-8
214. Stanley ER, Guilbert LJ, Tushimaki RJ. CSF-a. a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 1991; 21: 151-9
215. Wing EJ, Ampel NM, Waheed A, et al. Macrophage colony stimulating factor (M-CSF) enhances the capacity of murine macrophages to secrete oxygen reduction products. J Immunol 1985; 135: 2052-6
216. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida albicans by the colony stimulating factors (CSF): IL-3 granulocyte macrophage-CSF, and macrophage-CSF. J Immunol 1987; 143: 671-7
217. Kabassi A, Mecker JM, Foster JS, et al. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony stimulating factor: evidence for augmented expression of mannose receptors. J Immunol 1987; 139: 417-21
218. Moran KT, Allom M, O'Reilly TJ, et al. Neutrophil retro cellular kill following thermal injury. Arch Surg 1988; 123: 686-8
219. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84
220. Aukerman SC, Miffleton J, Sampson-Johanes A, et al. Biological and preclinical activity of macrophage colony stimulating factor, M-CSF. In: Symann M, Quesenberry P, editors. Hematopoietic growth factors: from the basic to the clinical applications. Macclesfield: Gardiner-Caldwell Communications, 1991: 38-46
221. Cenci E, Bartocci A, Puccetti P, et al. Macrophage colony stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immunol 1991; 59: 868-72
222. Yanai N, Yamada M, Motoyoshi K, et al. Effect of human macrophage colony stimulating factor on granulopoiesis and survival in bone marrow transplanted mice. Jpn J Cancer Res 1990; 81: 355-62
223. Broxmeyer HE, Williams DE, Copper S, et al. The influence in vivo of murine colony-stimulating factor-1 on myeloid progenitor cells in mice recovering from sublethal dosages of cyclophosphamide. Blood 1987; 69: 913-8
224. Chnong KT, Longlois L. Enhancing effect of macrophage colony stimulating factor (M-CSF) in leukocytes and host defense in normal and immunosuppressed mice. FASEB J 1988; 2: 1474-8
225. Nemunaitis J, Meyers D, Buckner CD, et al. Phase I trial of recombinant human macrophage colony stimulating factor in patients with invasive fungal infections. Blood 1991; 78 (4): 907-13
226. Nemunaitis J, Dorcy KS, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony stimulating factor. Blood 1993; 82 (5): 1422-7
227. Nemunaitis J. Macrophage function activating cytokines: potential clinical application. Crit Rev Oncol/Hematol 1993; 14: 153-71
228. Motoyoshi T, Takaku F. Human monocyte colony stimulating factor (hM-CSF). phase I/II clinical studies. In: Mertelsmann R, Hermann F, editors. Hematopoietic growth factors in clinical applications. New York: Marcel Dekker, 1990: 161-75
229. Masaoka T, Motohoshi K, Takaku F, et al. Administration of human urinary colony stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1988; 3: 121-7
230. Masaoka T, Shibata H, Ohno R, et al. Double blind test of human urinary macrophage colony stimulating factor for allogeneic and syngeneic bone marrow transplantation: effectiveness of treatment and 2-year follow-up for relapse of leukemia. Br J Haematol 1990; 76: 501-5
231. Ohno R, Miyawaki S, Hatake K, et al. Macrophage colony stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia (AML): a double blind controlled study [abstract]. Blood 1995; 86 (10): 266